Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.54 |
| ▸ | PGK1 | P00558 | 4/20 | 0.53 |
| ▸ | PGK2 | P07205 | 4/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738152 | 0.81 | PTPN1 (0.55) | PTPN1PGK1PGK2PTPN5PTPRC | |
| SCHEMBL3740717 | 0.79 | PTPN1 (0.54) | PTPN1PGK1PGK2PTPN5PTPRC | |
| SCHEMBL3737925 | 0.79 | PTPN1 (0.70) | PTPN1PGK1PGK2PTPN5 | |
| SCHEMBL4009974 | 0.76 | SMN1; SMN2 (0.36) | PTPN1SMN1; SMN2ALOX15ALDH1A1HSD17B10 | |
| SCHEMBL3743438 | 0.76 | PTPN1 (0.70) | PTPN1PGK1PGK2PTPN5 | |
| SCHEMBL3737962 | 0.76 | TSHR (0.51) | PTPN1PGK1PGK2PTPN5SMN1; SMN2 | |
| SCHEMBL2748456 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2ALOX15ALDH1A1HSD17B10TDP1 | |
| SCHEMBL29441420 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2ALOX15ALDH1A1HSD17B10TDP1 | |
| SCHEMBL6834136 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2ALOX15ALDH1A1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL27738830 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2ALOX15ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1812012-A2 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Ceptyr, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006055525-A2 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PGK1 1901/4885PGK2 1459/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PGK1 1901/4885PGK2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.